305 related articles for article (PubMed ID: 27788886)
1. Evaluation of long-term safety and efficacy of omalizumab in elderly patients with uncontrolled allergic asthma.
Tat TS; Cilli A
Ann Allergy Asthma Immunol; 2016 Nov; 117(5):546-549. PubMed ID: 27788886
[TBL] [Abstract][Full Text] [Related]
2. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
3. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
[TBL] [Abstract][Full Text] [Related]
4. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
[TBL] [Abstract][Full Text] [Related]
5. The relationship between allergen immunotherapy and omalizumab for treating asthma.
Braido F; Corsico A; Rogkakou A; Ronzoni V; Baiardini I; Canonica GW
Expert Rev Respir Med; 2015 Apr; 9(2):129-34. PubMed ID: 25578528
[TBL] [Abstract][Full Text] [Related]
6. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
7. [Severe uncontrolled asthma in patients over 75 years old: Treatment with omalizumab].
Romand P; Kelkel E; Saint-Raymond C; Glas N; Caillaud D; Devouassoux G
Rev Mal Respir; 2016 May; 33(5):397-400. PubMed ID: 26346416
[TBL] [Abstract][Full Text] [Related]
8. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
9. Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.
Dal Negro RW; Guerriero M; Micheletto C; Tognella S; Visconti M
J Asthma; 2011 Jun; 48(5):437-41. PubMed ID: 21599560
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, pharmacodynamics and clinical efficacy of omalizumab for the treatment of asthma.
Luu M; Bardou M; Bonniaud P; Goirand F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1503-1511. PubMed ID: 27748630
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
Massanari M; Kianifard F; Zeldin RK; Geba GP
Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
[TBL] [Abstract][Full Text] [Related]
13. A clinical follow-up of omalizumab in routine treatment of allergic asthma monitored by CD-sens.
Johansson SGO; Lilja G; Hallberg J; Nopp A
Immun Inflamm Dis; 2018 Sep; 6(3):382-391. PubMed ID: 29737044
[TBL] [Abstract][Full Text] [Related]
14. Influence of Omalizumab on Allergen-Specific IgE in Patients with Adult Asthma.
Mizuma H; Tanaka A; Uchida Y; Fujiwara A; Manabe R; Furukawa H; Kuwahara N; Fukuda Y; Kimura T; Jinno M; Ohta S; Yamamoto M; Matsukura S; Adachi M; Sagara H
Int Arch Allergy Immunol; 2015; 168(3):165-72. PubMed ID: 26790100
[TBL] [Abstract][Full Text] [Related]
15. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
Maselli DJ; Singh H; Diaz J; Peters JI
Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of response to omalizumab therapy in real life by a novel multimodular approach: The Real-life Effectiveness of Omalizumab Therapy (REALITY) study.
Singh H; Peters JI; Kaur Y; Maselli DJ; Diaz JD
Ann Allergy Asthma Immunol; 2019 Nov; 123(5):476-482.e1. PubMed ID: 31382020
[TBL] [Abstract][Full Text] [Related]
18. Real-life efficacy and safety of omalizumab in Portuguese patients with persistent uncontrolled asthma.
Pereira Barbosa M; Bugalho de Almeida A; Pereira C; Chen CW; Georgiou P; Peachey G;
Rev Port Pneumol (2006); 2015; 21(3):151-6. PubMed ID: 25926246
[TBL] [Abstract][Full Text] [Related]
19. Anti-immunoglobulin E therapy with omalizumab for asthma.
Hendeles L; Sorkness CA
Ann Pharmacother; 2007 Sep; 41(9):1397-410. PubMed ID: 17698897
[TBL] [Abstract][Full Text] [Related]
20. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
Rodrigo GJ; Neffen H
Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
